Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase Inhibitors

Tsung-Che Wu¹, Chia-Chi Lin²

Affiliations

¹ Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Department of Oncology, National Taiwan University Biomedical Park Hospital, Hsinchu, Taiwan.
² Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: cclin1@ntu.edu.tw.

PMID: 36031284
DOI: 10.1016/j.jtho.2022.06.012

Free article

Editorial

Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase Inhibitors

Tsung-Che Wu et al. J Thorac Oncol. 2022 Sep.

Free article

. 2022 Sep;17(9):1063-1066.

doi: 10.1016/j.jtho.2022.06.012.

Authors

Tsung-Che Wu¹, Chia-Chi Lin²

Affiliations

¹ Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Department of Oncology, National Taiwan University Biomedical Park Hospital, Hsinchu, Taiwan.
² Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: cclin1@ntu.edu.tw.

PMID: 36031284
DOI: 10.1016/j.jtho.2022.06.012

No abstract available

PubMed Disclaimer

Comment on

Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study.
Kenmotsu H, Wakuda K, Mori K, Kato T, Sugawara S, Kirita K, Yoneshima Y, Azuma K, Nishino K, Teraoka S, Shukuya T, Masuda K, Hayashi H, Toyozawa R, Miura S, Fujimoto D, Nakagawa K, Yamamoto N, Takahashi T. Kenmotsu H, et al. J Thorac Oncol. 2022 Sep;17(9):1098-1108. doi: 10.1016/j.jtho.2022.05.006. Epub 2022 May 27. J Thorac Oncol. 2022. PMID: 35636696 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase Inhibitors

Affiliations

Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase Inhibitors

Authors

Affiliations

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous